PMID- 26842723
OWN - NLM
STAT- MEDLINE
DCOM- 20161219
LR  - 20220331
IS  - 1432-1750 (Electronic)
IS  - 0341-2040 (Linking)
VI  - 194
IP  - 2
DP  - 2016 Apr
TI  - Stereotactic Body Radiotherapy (SBRT) with Lower Doses for Selected Patients with 
      Stage I Non-small-cell Lung Cancer (NSCLC).
PG  - 291-4
LID - 10.1007/s00408-016-9849-4 [doi]
AB  - SBRT is very effective for stage I NSCLC. Biologically effective doses (BED) 
      >100 Gy are recommended. Elderly patients and those with a limited performance 
      status may not tolerate these high doses. This study investigated the outcomes 
      after lower dose SBRT (BED < 90 Gy) in 46 patients with stage I NSCLC, who were 
      aged >/=70 years or in reduced general condition. Local control rates at 1, 2, and 
      3 years were 100, 95, and 95 %, respectively. Rates of freedom from distant 
      progression were 83, 63, and 54 %, and survival rates were 77, 57, and 36 %, 
      respectively. Seventeen patients died during the follow-up, 11 (65 %) from 
      distant progression of NSCLC, and six (35 %) from non-malignant causes. No 
      patient developed radiation-induced pneumonitis. Thus, SBRT with BED <90 Gy 
      resulted in excellent local control and appears to be a reasonable option for 
      stage I NSCLC in elderly patients and those with a poor performance status.
FAU - Janssen, Stefan
AU  - Janssen S
AD  - Department of Radiation Oncology, University of Lubeck, Ratzeburger Allee 160, 
      23538, Lubeck, Germany.
AD  - Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany.
FAU - Kaesmann, Lukas
AU  - Kaesmann L
AD  - Department of Radiation Oncology, University of Lubeck, Ratzeburger Allee 160, 
      23538, Lubeck, Germany.
FAU - Rudat, Volker
AU  - Rudat V
AD  - Department of Radiation Oncology, Saad Specialist Hospital, Al Khobar, Saudi 
      Arabia.
FAU - Rades, Dirk
AU  - Rades D
AD  - Department of Radiation Oncology, University of Lubeck, Ratzeburger Allee 160, 
      23538, Lubeck, Germany. rades.dirk@gmx.net.
LA  - eng
PT  - Journal Article
DEP - 20160203
PL  - United States
TA  - Lung
JT  - Lung
JID - 7701875
SB  - IM
MH  - Aged
MH  - Carcinoma, Non-Small-Cell Lung/mortality/pathology/*radiotherapy
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/mortality/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Patient Selection
MH  - *Radiation Dosage
MH  - Radiation Pneumonitis/etiology
MH  - *Radiosurgery/adverse effects/mortality
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Biologically effective dose
OT  - Early stage
OT  - Non-small-cell lung cancer
OT  - Stereotactic body radiotherapy
OT  - Treatment results
EDAT- 2016/02/05 06:00
MHDA- 2016/12/20 06:00
CRDT- 2016/02/05 06:00
PHST- 2015/12/09 00:00 [received]
PHST- 2016/01/25 00:00 [accepted]
PHST- 2016/02/05 06:00 [entrez]
PHST- 2016/02/05 06:00 [pubmed]
PHST- 2016/12/20 06:00 [medline]
AID - 10.1007/s00408-016-9849-4 [pii]
AID - 10.1007/s00408-016-9849-4 [doi]
PST - ppublish
SO  - Lung. 2016 Apr;194(2):291-4. doi: 10.1007/s00408-016-9849-4. Epub 2016 Feb 3.